Table 1.
Fracture rates comparing rosiglitazone with metformin or glyburide in ADOPT study. Table adapted from a Letter to Health Care Providers issued by GSK [4].
| Rosiglitazone | Metformin or glyburide | Relative rate (95% CI) | ||||
|---|---|---|---|---|---|---|
| Women | ||||||
| Total followup (P-Y) | 2187.20 | 3578.80 | ||||
|
| ||||||
| Fracture site | N | Rate/100PY | N | Rate/100PY | RR | (95% CI) |
|
| ||||||
| Lower limb* | 36 | 1.65 | 26 | 0.73 | 2.27 | (1.33, 3.91) |
| Hip | 2 | 0.09 | 2 | 0.06 | 1.64 | (0.12, 22.57) |
| Foot | 22 | 1.01 | 11 | 0.31 | 3.27 | (1.52, 7.47) |
| Upper limb† | 22 | 1.01 | 19 | 0.53 | 1.89 | (0.98, 3.70) |
| Hand | 8 | 0.37 | 5 | 0.14 | 2.62 | (0.76, 10.17) |
| Humerus | 5 | 0.23 | 0 | 0.00 | ‡ | (1.50,‡) |
| Spine | 1 | 0.05 | 2 | 0.06 | 0.82 | (0.01, 15.72) |
| Other | 5 | 0.23 | 8 | 0.22 | 1.02 | (0.26, 3.55) |
|
| ||||||
| All fractures | 64 | 2.93 | 55 | 1.54 | 1.90 | (1.31, 2.78) |
|
| ||||||
| Men | ||||||
| Total followup (P-Y) | 2766.70 | 5570.40 | ||||
|
| ||||||
| N | Rate/100PY | N | Rate/100PY | RR | (95% CI) | |
| Total participants with any fracture | 32 | 1.16 | 57 | 1.02 | 1.13 | (0.71, 1.77) |
* Hip, foot, ankle, femur, fibula, lower limb (general), patella, tibia.
† Hand, humerus, clavicle, forearm, radius, upper limb (general), wrist.
‡ Cannot estimate. No events in the comparison group.
Reprinted with permission from [5]